Weight-Loss Drugs Like Ozempic May Come With an Unexpected Cost
Glucagon-like peptide-1 (GLP-1) medications are drugs used to treat type 2 diabetes and support weight loss. They mimic…
Pfizer (PFE) earnings Q1 2026
Exterior view of the Pfizer headquarters building on January 29, 2023 in New York City. View Press |…
FDA withdrew studies finding Covid, shingles vaccines were safe
The FDA blocked the publication of several studies supporting the safety of vaccines against Covid and shingles in…
UnitedHealth, Cigna, Humana earnings show insurers are recovering
Piotr Swat | SOPA Images | Lightrocket | Getty Images Major health insurers appear to be off to…
Apotex becomes the first Canadian‑based pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic®
TORONTO, May 1, 2026 /PRNewswire/ – Apotex Inc. (“Apotex” or the “Company”), Canada’s largest Canadian‑based global health company,…
How to handle a high health insurance deductible
A still from Netflix’s ‘Beef.’ Courtesy: Netflix In the new season of the Netflix comedy-drama, “Beef,” Ashley, played…
FDA proposes excluding Novo, Lilly GLP-1s from compounding list
The headquarters of the U.S. Food and Drug Administration in Silver Spring, Maryland, Nov. 4, 2009. Jason Reed…
Eli Lilly (LLY) earnings Q1 2026
Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past estimates and hiked its full-year sales…
Reality of Trump’s drug pricing to set in over next 18 months
Novartis‘ CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a “very difficult…
Crispr gene editing treatment from Intellia succeeds in Phase 3 trial
Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA. Spencer Grant | Universal Images Group | Getty…
UnitedHealth Group (UNH) earnings Q1 2026
UnitedHealthcare sign is displayed at its office building in Minnetonka, Minnesota, U.S., Dec. 11, 2025. Tim Evans |…
Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
Kelonia’s lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for…